'Anti-alcoholism' drug cleared for use in France

April 25, 2012

French health authorities have approved the use of a drug, originally designed to treat nervous spasms, for the treatment of alcoholism on a "case by case" basis.

AFSSAPS, the regulator that authorises drugs, said that while the Baclofen had not been definitively shown to be efficient in the treatment of alcoholism, it had shown "clinical benefits in some patients".

It recommended in a statement that Baclofen -- the lab name for a medication branded as Kemstro, Lioresal and Gablofen -- should be considered on a "case by case" basis.

The history of the drug goes back 50 years. It was originally designed for epilepsy before becoming licensed to treat spasticity, but researchers are now interested in using it to ease alcoholic craving.

Interest was sparked in 2008 by a book, "Le Dernier Verre" (The Last Drink), by cardiologist Olivier Ameisen, who self-treated his alcoholism with high doses of Baclofen.

The AFSSAPS statement came after French doctors said last month that the drug had cleared an important early test. The trial entailed enrolling 132 who were given Baclofen at high doses over a year.

Eighty percent either became abstinent or turned into . By comparison, two drugs that are commonly used to treat alcoholics, naltrexon and , yield a success rate of 20-25 percent.

Side effects included fatigue, drowsiness, insomnia, dizziness and digestive troubles.

Lead researcher Philippe Jaury of the University of Paris-Descartes said the outcome opened the door to one-year clinical trials, expected to start in May, in which 320 alcoholics would be divided into two groups.

One batch will receive Baclofen, progressively building in dosage until the craving symptoms subside, while the others will receive an inactive look-a-like pill, or placebo.

France's health system is paying 750,000 euros ($469,000) of the 1.2-million-euro ($1.45-million) cost of the trial, and an unidentified donor is paying the rest, Jaury told AFP.

The pre-trial study was published in a specialist journal, and Alcoholism.

Explore further: 'Anti-alcoholism' drug clears key test hurdle

Related Stories

'Anti-alcoholism' drug clears key test hurdle

March 20, 2012
A drug designed to treat nervous spasms has cleared an important early test in a project to see whether it can also cure alcoholism, French doctors said on Tuesday.

New clinical trial to examine medication to treat social withdrawal in Fragile X and autism

July 20, 2011
Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug ...

New drug may reduce seizures in epilepsy

April 13, 2011
A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug. The late-breaking ...

Recommended for you

Certain teens more likely to get hooked on opioids

March 12, 2018
(HealthDay)—Teenagers with any mental health problem are more prone to painkiller dependence after receiving a prescription opioid, a new study finds.

Prescription opioids fail rigorous new test for chronic pain

March 6, 2018
A yearlong study offers rigorous new evidence against using prescription opioids for chronic pain.

Study suggests failed osteoarthritis drug could help treat opioid addiction

February 27, 2018
A new study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used in combination with opioid-based pain medications.

Complex inhalers prevent patients from taking medicine

February 23, 2018
Respiratory disease patients with arthritis could struggle to manage their conditions because their inhalers are too fiddly for them to use, University of Bath research has found.

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.